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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2015, Taiwan S
BY-NC-ND license (http://creativecomA 3-year-old boy with Mycoplasma pneumoniae infection associated with hemophagocytic lym-
phohistiocytosis (MP-HLH) presented with an elevated level of serum interleukin-12 (IL-12) and
lower levels of interferon-g and IL-10 compared to patients with EpsteineBarr virus infection
associated with HLH (EBV-HLH). Unlike the patients with EBV-HLH, CD8þ CD5low HLA-DRþþ T
cells were not detected in our pediatric patient. Thus, the pathophysiology of MP-HLH may
differ from that of EBV-HLH.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a hyper-
inflammatory syndrome characterized by the uncontrolled
activation and massive proliferation of macrophages and Tt of Pediatrics, Faculty of
23-3 Shimoaizuki, Matsuoka,
n.
ac.jp (M. Yasutomi).
.11.015
ociety of Microbiology. Published
mons.org/licenses/by-nc-nd/4.0/cells with hypercytokinemia.1 Although HLH and Myco-
plasma pneumoniae (MP) infection can be comorbid, the
mechanism of the pathogenesis remains unclear. Here we
report on the changes in peripheral blood T-cell subsets and
serum cytokine profiles observed in a boy with MP infection
associated with HLH (MP-HLH).
Case report
A 3-year-old boy was admitted to a hospital with persisting
fever and coughs for 4 days. He had been healthy beforeby Elsevier Taiwan LLC. This is an open access article under the CC
).
814 M. Yasutomi et al.the onset of fever. A chest radiograph revealed massive
infiltration in the right upper lung lobe, suggesting pneu-
monia. He was initially treated with clarithromycin and
ampicillin/sulbactam, which were replaced with mer-
openem and minocycline, due to the possibility of
penicillin-resistant Streptococcus pneumoniae and
macrolide-resistant M. pneumoniae as causative agents.C
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Figure 1. (A) Bone marrow smear revealed hemophagocytosis by
CD8þ T cells. CD5 downregulation was detected in EpsteineBarr v
but not in Mycoplasma pneumoniae-associated HLH (MP-HLH). Value
expressing T cells. (C) Serum cytokine levels in MP-HLH, EBV-HLH,
Serum interleukin-2 (IL-2), IL-4, and IL-17 were not detected. IFN-Because of a persistent high-grade fever and elevated
serum levels of lactate dehydrogenase (LDH) and ferritin,
the boy was referred to our hospital 4 days later. On
admission, his laboratory findings were as follows: white
blood cell count, 4800/mL (neutrophils, 57.6%); hemoglo-
bin, 11.9 g/dL; platelets, 116,000/mL; serum C-reactive
protein, 59.4 mg/L (normal <3.2 mg/L); aspartateMP-HLH EBV-HLH
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macrophage. (B) Flow cytometric analysis of CD5 expression on
irus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)
s represent the percentage of the respective surface molecules
and severe MP patients before corticosteroid administration.
g Z interferon-g; TNF-a Z tumor necrosis factor-a.
Cytokine profiles in mycoplasma HLH 815aminotransferase, 1788 IU/L; alanine aminotransferase,
332 IU/L; LDH, 3748 IU/L; ferritin, 7718 ng/mL (normal,
18.6e261 ng/mL); soluble interleukin-2 (IL-2) receptor,
2686 U/mL (normal, 144.5e518 U/mL); and fibrinogen,
143 mg/dL (normal, 140e340 mg/dL). The passive aggluti-
nation test titers for MP were 1:2560 on Day 10, which
increased to 1:20,480 on Day 32. Both cytomegalovirus
antigenemia and anti-EpsteineBarr virus (EBV) antibodies
were negative. Natural killer (NK) cell cytotoxicity was
18.9% (normal >18%). Bone marrow aspiration exhibited
normal cellularity with increased hemophagocytic macro-
phages (Fig. 1A). The patient was diagnosed with MP-HLH
according to the HLH-2004 criteria and was treated with
intravenous immunoglobulin (IVIG, 2 g/kg) and predniso-
lone (2.6 mg/kg/d). His symptoms and laboratory findings
improved within a few days. The prednisolone dose was
gradually tapered and then stopped when no recurrence
was noted 13 days after admission.
To understand the pathophysiology of MP-HLH, we
examined the patient’s peripheral blood T-cell subsets and
serum cytokine profiles. Because an increase in CD8þ
CD5low HLA-DRþþ T cells is a characteristic feature of EBV
infection associated with HLH (EBV-HLH)2 and familial HLH
type 2 (FHL2),3 whole blood from the patient was stained
with antihuman leukocyte antigen (HLA)-DR (Ancell, Bay-
port, MN, USA), antihuman CD5, antihuman CD8, or anti-
human CD3 (all from Affymetrix eBioscience, San Diego, CA,
USA) monoclonal antibodies (mAbs). CD5 expression on
CD8þ T cells was evaluated with a FACSCalibur flow cy-
tometer using CellQuest (BD Biosciences, San Jose, CA,
USA). CD5 expression was considered negative if the level
was similar to those of NK cells and CD5-negative B cells. A
patient with nonfamilial EBV-HLH diagnosed using the HLH-
2004 criteria was used as a positive control (Table 1). As
shown in Fig. 1C, lymphocytes from the MP-HLH patient had
a lower percentage of HLA-DRþþ activated T cells than
those from the EBV-HLH patient. In contrast to the EBV-HLH
case, few, if any, CD8þ CD5low HLA-DRþþ T cells were
detected in the peripheral blood of the MP-HLH patient.
We compared the patient’s serum cytokine profiles prior
to commencement of steroid treatment with those of four
patients with severe MP infection who requiredTable 1 Demographic data of the patients.
Case (age/sex) MP-HLH
3 y/M
MP1
6 y/M
Minimum SpO2 (%) 90 92
Maximum ferritin (ng/mL) 7718 377
Anti-Mycoplasma
pneumoniae PA
Acute 2560 1280
Convalescent >20,480 20,480
Antibiotics CAM, ABPC/SBT,
MEPM, and MINO
AZM, CLDM,
and MINO
Immunotherapy PLS and IVIG PLS
ABPC/SBT Z ampicillin/sulbactam; AZM Z azithromycin; CAM Z
EBV-HLH Z EpsteineBarr virus-associated HLH; HLH Z hemophago
MEPM Z meropenem; MINO Z minocycline; MP Z mycoplasmal pneu
hemophagocytic lymphohistiocytosis (HLH); n.d. Z not determine
CFDN Z cefdinir; PA Z passive agglutination.supplementary steroid therapy due to respiratory distress
or fever lasting more than 7 days, and those of a patient
with EBV-HLH (Table 1). Informed consent was obtained
from the parents in accordance with the Declaration of
Helsinki. The serum concentrations of cytokines were
determined using a BD cytometric bead array human Th1/
Th2/Th17 kit (BD Biosciences) and a sandwich enzyme-
linked immunosorbent assay with antihuman IL-18 mAbs
(MBL, Nagoya, Japan), according to the manufacturer’s
instructions. As shown in Fig. 1C, both MP-HLH and EBV-HLH
showed higher serum IL-12 levels than severe MP. IL-2, IL-4,
and IL-17 were not detectable in any of the sera. There was
no significant difference in the serum levels of the other
examined cytokines between MP-HLH and severe MP. Of
note, the elevated serum interferon-g (IFN- g) and IL-10
levels were much lower than those of EBV-HLH.Discussion
HLH is roughly classified into two forms, namely, familial
(genetic) and secondary (acquired). Secondary HLH is
associated with a variety of underlying conditions including
infections, autoimmune diseases, or malignancy.1 EBV-HLH
is well-known to be prototypic of secondary HLH, whereas
MP-HLH is rare. Most cases of MP-HLH have been shown to
exhibit relatively mild cytopenia and good therapeutic
responsiveness to systemic corticosteroids.4,5 Consistent
with previous reports, the present case was well controlled
using a corticosteroid and IVIG.
FHL is caused by mutations that impair the cytotoxicity
of NK cells and CD8 T cells, which kill both infected cells
and antigen-presenting cells, to remove antigens and to
terminate immune responses.1 Viral infections generally
trigger the development of FHL symptoms, resulting in
persistent activation and proliferation of lymphocytes,
followed by the uncontrolled secretion of proinflammatory
cytokines. CD8 T cells producing high levels of IFN-g play a
critical role in the pathogenesis of FHL.3,6 The down-
regulation of CD5 observed in patients with EBV-HLH and
FHL2 is considered a consequence of the dysregulated
proliferation of CD8þ T cells. The increase in CD8þ CD5lowMP2
11 y/F
MP3
3 y/F
MP4
4 y/M
EBV-HLH
4 y/F
90 96 89 99
n.d. n.d. n.d. 1247
<40 160 n.d. EBV-PCR (þ)
1280 2560 5120
CAM, ABPC/SBT,
and MINO
CFDN, CAM,
and CLDM
CAM, AZM,
ABPC/SBT,
and CLDM
AZM and MEPM
PLS PLS PLS PLS, CsA, and
etoposide
clarithromycin; CLDM Z clindamycin; CsA Z cyclosporine A;
cytic lymphohistiocytosis; IVIG Z intravenous immunoglobulin;
monia; MP-HLH Z Mycoplasma pneumoniae infection-associated
d; PCR Z polymerase chain reaction; PLS Z prednisolone;
816 M. Yasutomi et al.HLA-DRþþ T cells is correlated with the severity of FHL2 or
EBV-HLH.2,3 However, the role of these subpopulations in
the other form of HLH remains unknown. Animal models of
HLH have shown that pathogenic IFN-g production could be
attributed to other cells rather than CD8þ T cells,
depending on the underlying conditions.7,8 Considering the
lack of CD8þ CD5low HLA-DRþþ T cells, cells other than the
CD8þ T-cell subpopulation produced low levels of IFN-g in
MP-HLH, resulting in mild HLH.
IL-12 is well-known to enhance IFN-g production by Th1
cells, CD8þ T cells, and NK cells. Although administered
antibiotics might modify the cytokine profile, the IFN-g
levels observed in MP-HLH were much lower than that of
EBV-HLH despite the similar levels of IL-12, supporting the
notion that the extremely high levels of IFN-g in EBV-HLH
could be explained by dysregulation of EBV-infected CD8þ
T cells.
IL-18 is a proinflammatory cytokine that enhances the
activity of NK cells and induces IFN-g production in concert
with IL-12. Elevation of serum IL-18 levels is reported in
patients with X-linked inhibitor of apoptosis deficiency-
associated HLH.9 Serum IL-18 levels can also be elevated in
patients with MP.10 Whereas the IL-18 levels of the present
case were not as high as those of severe MP, IL-18 levels
merely reflect the severity of MP rather than the comor-
bidity of HLH, as postulated by Tanaka et al.10
In the present case, NK cytotoxic activity was close to
the lower normal limit. Although the role of NK cell cyto-
toxicity in protection against mycoplasmal infection is un-
certain, poor NK cytotoxic activity might account for
vulnerability to mycoplasmal infection and the develop-
ment of MP-HLH. Overall, the underlying pathophysiology
of MP-HLH may differ from that of EBV-HLH.
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